Novo Nordisk A/S
NONOF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $2,756 | $3,110 | $2,148 | $1,667 |
| - Cash | $16 | $14 | $13 | $11 |
| + Debt | $103 | $27 | $26 | $27 |
| Enterprise Value | $2,843 | $3,123 | $2,161 | $1,683 |
| Revenue | $290 | $232 | $177 | $141 |
| % Growth | 25% | 31.3% | 25.7% | – |
| Gross Profit | $246 | $196 | $149 | $117 |
| % Margin | 84.7% | 84.6% | 83.9% | 83.2% |
| EBITDA | $137 | $111 | $77 | $65 |
| % Margin | 47.3% | 47.8% | 43.4% | 46% |
| Net Income | $101 | $84 | $56 | $48 |
| % Margin | 34.8% | 36% | 31.4% | 33.9% |
| EPS Diluted | 22.64 | 9.31 | 12.22 | 10.37 |
| % Growth | 143.2% | -23.8% | 17.8% | – |
| Operating Cash Flow | $121 | $109 | $79 | $55 |
| Capital Expenditures | -$51 | -$39 | -$15 | -$7 |
| Free Cash Flow | $70 | $70 | $64 | $48 |